Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13): Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2024;56(4):1136-1145. Published online April 29, 2024; DOI: https://doi.org/10.4143/crt.2023.1324

Abstract PDF Supplementary Material PubReader ePub

Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Materials and Methods
Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity.
Results
RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D.
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.

Citations

Citations to this article as recorded by

Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy
Sixiang Zheng, Ruixian Chen, Lele Zhang, Lun Tan, Lintao Li, Fangyi Long, Ting Wang
European Journal of Medicinal Chemistry.2024; 276: 116702. CrossRef

1,550 View
117 Download
1 Web of Science
1 Crossref

Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study: So Yeon Oh, Su-Jin Koh, Ji Yeon Baek, Kyung A Kwon, Hei-Cheul Jeung, Kyung Hee Lee, Young-Woong Won, Hyun Jung Lee; Cancer Res Treat. 2019;51(4):1612-1619. Published online April 12, 2019; DOI: https://doi.org/10.4143/crt.2018.505

Abstract PDF PubReader ePub

Purpose
Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. Nutrition risk screening aims to increase awareness and allow early recognition and treatment of cancer cachexia. Therefore, screenings should be brief, inexpensive, highly sensitive, and have good specificity. Simplified Nutritional Appetite Questionnaire (SNAQ) is a simple screening tool including four questions, and validated to predict weight loss within 6 months in community-dwelling adults and nursing home residents. Our study aimed to translate the SNAQ into Korean, and to assess the validity and reliability of the translated screening tool in advanced cancer patients.
Materials and Methods
The SNAQ was translated into Korean according to linguistic validation. The internal consistency of the SNAQ was evaluated by Cronbach’s alpha coefficient. Test-retest reliability was evaluated using the intraclass correlation coefficient. Concurrent validity was evaluated by measuring the Pearson’s correlation coefficient between the SNAQ and Mini-Nutritional Assessment (MNA) and Patient-Generated Subjective Global Assessment (PG-SGA).
Results
In the 194 patients included in full analysis set, cancer stage was predominantly metastatic (98.5%), the mean age was 60 years (range, 23 to 81 years), and the mean body mass index was 24 kg/m2 (range, 15.6 to 39.6 kg/m2). According to MNA score ≤ 11, 57 patients (29.4%) were malnourished. The mean score (±standard deviation) of the Korean version of the SNAQ was 13.8±2.5 with a range of 6-19. Cronbach’s alpha coefficient was 0.737, and intraclass correlation coefficient was 0.869. The SNAQ was moderately correlated with MNA (r=0.404, p < 0.001) and PG-SGA (r=–0.530, p < 0.001). A significant weight loss of > 5% of the original bodyweightwithin 6 months occurred in 46 of the 186 patients (24.7%). SNAQ score ≤ 14 predicted > 5% weight loss with a sensitivity of 56.5% and a specificity of 44.3%.
Conclusion
The Korean version of the SNAQ had high validity and reliability. SNAQ is useful for the screening tool for advanced cancer patients. The SNAQ had a limitation to predict impending weight loss in advanced cancer patients.

Citations

Citations to this article as recorded by

Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef
Therapeutic Potential of Combined Herbal Medicine and Electroacupuncture in Mild Cognitive Impairment Through Cytokine Modulation: An Observational Study
Jung-Hee Jang, Hyeong Joon Jun, ChaYoung Lee, Eunjin Sohn, Ojin Kwon, Dong-Hoon Kang, Muhammad Umar, In Chul Jung, Soo-Jin Jeong
Neuropsychiatric Disease and Treatment.2024; Volume 20: 1331. CrossRef
Reliability and validity of Chinese version of the Simplified Nutritional Appetite Questionnaire (SNAQ) in community-dwelling old people
Gaojie Feng, Xiaohong Sun, Qiumei Wang, Fei Lu, Yuanyuan Li, Yaru Zhou, Xiaohong Liu
Geriatric Nursing.2024; 59: 351. CrossRef
Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations
Elaine B. Trujillo, Kunal C. Kadakia, Cynthia Thomson, Fang Fang Zhang, Alicia Livinski, Kim Pollard, Todd Mattox, Anne Tucker, Valaree Williams, Declan Walsh, Steven Clinton, Aaron Grossberg, Gordon Jensen, Rhone Levin, Jeannine Mills, Anurag Singh, Mere
Journal of Parenteral and Enteral Nutrition.2024; 48(8): 874. CrossRef
Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
Konstantina Vamvakari, Iliana Evangelou, Ioanna Panagiota Kalafati, Michail Kipouros, Rena I. Kosti, Arezina N. Kasti, Odysseas Androutsos
memo - Magazine of European Medical Oncology.2023; 16(3): 200. CrossRef
AIWW: a new nutrition-screening tool for the oncologic population
Yi-Zhong Ge, Zhen-Ming Fu, Qi Zhang, Meng-Meng Song, Guo-Tian Ruan, Xi Zhang, Xiao-Wei Zhang, Xiang-Rui Li, Kang-Ping Zhang, Meng Tang, Xiao-Yue Liu, Ming Yang, Tong Liu, Hai-Lun Xie, He-Yang Zhang, Zi-Wen Wang, Chun-Lei Hu, Shi-Qi Lin, Rui Zhang, Hong-Xi
Science China Life Sciences.2023; 66(8): 1831. CrossRef
Validation of a telephone‐based administration of the simplified nutritional appetite questionnaire
Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1848. CrossRef
Faeces from malnourished colorectal cancer patients accelerate cancer progression
Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
Clinical Nutrition.2022; 41(3): 632. CrossRef
Influence of cognitive function and nurse support on malnutrition risk in nursing home residents
Annamária Pakai, Emese Havasi‐Sántha, Erzsébet Mák, Orsolya Máté, Dorina Pusztai, Noémi Fullér, Miklós Zrínyi, András Oláh
Nursing Open.2021; 8(4): 1805. CrossRef
Effectiveness of Oral Nutritional Supplements on Older People with Anorexia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mengqi Li, Si Zhao, Shuang Wu, Xiufen Yang, Hui Feng
Nutrients.2021; 13(3): 835. CrossRef
Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression
Yajun Wang, Shan Ye, Lu Chen, Lu Tang, Dongsheng Fan
Scientific Reports.2021;[Epub] CrossRef
Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
Clinical Therapeutics.2021; 43(10): 1757. CrossRef
Development of Korean Frailty Index for Primary Care (KFI-PC) and Its Criterion Validity
Chang Won Won, Yunhwan Lee, Seoyoon Lee, Miji Kim
Annals of Geriatric Medicine and Research.2020; 24(2): 125. CrossRef
The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults
Sabrina Lau, Kalene Pek, Justin Chew, Jun Pei Lim, Noor Hafizah Ismail, Yew Yoong Ding, Matteo Cesari, Wee Shiong Lim
Nutrients.2020; 12(9): 2885. CrossRef

7,997 View
205 Download
14 Web of Science
14 Crossref

Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer: Hyung Soon Park, Ji Soo Park, You Jin Chun, Yun Ho Roh, Jieun Moon, Hong Jae Chon, Hye Jin Choi, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Hei-Cheul Jeung; Cancer Res Treat. 2017;49(4):1127-1139. Published online February 6, 2017; DOI: https://doi.org/10.4143/crt.2016.538

Abstract PDF Supplementary Material PubReader ePub

Purpose
Metastatic biliary tract cancer (mBTC) has a dismal prognosis. In this study, an independent dataset of patients with mBTC was used to implement and validate a routine clinico-laboratory parameter-based scoring model for risk group identification.
Materials and Methods
From September 2006 to February 2015, 482 patients with mBTC were assigned randomly (ratio, 7:3) into investigational (n=340) and validation datasets (n=142). The continuous variables were dichotomized using a normal range or the best cutoff values determined using the Contal and O'Quigley statistical methods. Following a Cox’s proportional hazard model, the scoring model was derived by summing the rounded chi-square scores for the factors identified by multivariate analysis.
Results
The performance status (Eastern Cooperative Oncology Group 3-4), hypoalbuminemia (< 3.4 mg/dL), carcinoembryonic antigen (≥ 9 ng/mL), neutrophil-to-lymphocyte ratio (≥ 3.0), and carbohydrate antigen 19-9 (≥ 120 U/mL) were identified as independent prognosticators (Harrell’s C index, 0.682; integrated area under the curve, 0.653). Survival was clearly correlated with the risk groups (low, intermediate, and high, 14.0, 7.3, and 2.3 months, respectively; p < 0.001). The prognosis was also discriminative in the validation data set (median survival, 16.7, 7.5, and 1.9 months, respectively; p < 0.001). Chemotherapy did not offer any survival benefits for high-risk patients.
Conclusion
These proposed prognostic criteria for mBTC can facilitate accurate patient risk stratification and treatment-related decision-making.

Citations

Citations to this article as recorded by

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu
Cancer Research and Treatment.2024; 56(2): 602. CrossRef
Novel Prognostic Model Construction of Tongue Squamous Cell Carcinoma Based on Apigenin-Associated Genes
Jianfei Lai, Chen Fang, Guohua Zhang, Chao Shi, Feng Yu, Weiguo Gu, Jianxiong Deng, Jingbiao Xu, Chaoxing Liu, Feng Qiu
Frontiers in Bioscience-Landmark.2024;[Epub] CrossRef
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai
The Oncologist.2023; 28(6): 531. CrossRef
Development of a nomogram to predict survival in advanced biliary tract cancer
Hiroshi Imaoka, Masafumi Ikeda, Shogo Nomura, Chigusa Morizane, Takuji Okusaka, Masato Ozaka, Satoshi Shimizu, Kentaro Yamazaki, Naohiro Okano, Kazuya Sugimori, Hirofumi Shirakawa, Nobumasa Mizuno, Sohei Satoi, Hironori Yamaguchi, Rie Sugimoto, Kunihito G
Scientific Reports.2023;[Epub] CrossRef
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
Giulia Rovesti, Francesco Leone, Giovanni Brandi, Lorenzo Fornaro, Mario Scartozzi, Monica Niger, Changhoon Yoo, Francesco Caputo, Roberto Filippi, Mariaelena Casagrande, Nicola Silvestris, Daniele Santini, Luca Faloppi, Andrea Palloni, Massimo Aglietta,
Journal of Gastrointestinal Cancer.2022; 53(2): 289. CrossRef
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis
Roberto Filippi, Francesco Leone, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Nicola Silvestris, Andrea Palloni, Maria Antonietta Satolli, Mario Scartozzi, Marco Russano, Stefania Eufemia Lutrino, Pasquale Lombardi, Giorgio Frega, Silvio Ken
Journal of Chemotherapy.2022; 34(2): 123. CrossRef
Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W.R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Ror
JCO Precision Oncology.2022;[Epub] CrossRef
Pre-treatment Nutritional Risk Assessment by NRS-2002 Predicts Prognosis in Patients With Advanced Biliary Tract Cancer: A Single Center Retrospective Study
Se Eung Oh, Juong Soon Park, Hei-Cheul Jeung
Clinical Nutrition Research.2022; 11(3): 183. CrossRef
Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari
Cancer Treatment and Research Communications.2021; 28: 100431. CrossRef
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
Roberto Filippi, Francesco Montagnani, Pasquale Lombardi, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Luca Faloppi, Andrea Palloni, Maria Antonietta Satolli, Mario Scartozzi, Fabrizio Citarella, Stefania Eufemia Lutrino, Caterina Vivaldi, Ni
Acta Oncologica.2021; 60(10): 1317. CrossRef
Second-line therapies in advanced biliary tract cancers
Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal
The Lancet Oncology.2020; 21(1): e29. CrossRef
The neonatal Fc receptor in cancer FcRn in cancer
Diana Cadena Castaneda, Guillaume Brachet, Caroline Goupille, Lobna Ouldamer, Valérie Gouilleux‐Gruart
Cancer Medicine.2020; 9(13): 4736. CrossRef
Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients
Byung min Lee, Yeona Cho, Jun Won Kim, Hei Cheul Jeung, Ik Jae Lee
Frontiers in Oncology.2020;[Epub] CrossRef
Construction of a Five-Super-Enhancer-Associated-Genes Prognostic Model for Osteosarcoma Patients
Zhanbo Ouyang, Guohua Li, Haihong Zhu, Jiaojiao Wang, Tingting Qi, Qiang Qu, Chao Tu, Jian Qu, Qiong Lu
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
Yuko Suzuki, Motoyasu Kan, Gen Kimura, Kumiko Umemoto, Kazuo Watanabe, Mitsuhito Sasaki, Hideaki Takahashi, Yusuke Hashimoto, Hiroshi Imaoka, Izumi Ohno, Shuichi Mitsunaga, Masafumi Ikeda
Journal of Gastroenterology.2019; 54(3): 281. CrossRef
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Min su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee, Yong-Tae Kim
BMC Cancer.2019;[Epub] CrossRef
Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study
Anna Song, Wankyu Eo, Sehyun Kim, Bumsang Shim, Sookyung Lee
BMC Complementary and Alternative Medicine.2018;[Epub] CrossRef
Platelet to lymphocyte ratio in biliary tract cancer: Review and meta-analysis
Lin-hua Zhou, Xiao-feng Luo
Clinica Chimica Acta.2017; 474: 102. CrossRef

11,526 View
259 Download
17 Web of Science
18 Crossref

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma: Hyung Soon Park, Hye Sun Lee, Ji Soo Park, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Min Goo Lee, Hei-Cheul Jeung; Cancer Res Treat. 2016;48(4):1253-1263. Published online February 3, 2016; DOI: https://doi.org/10.4143/crt.2015.400

Abstract PDF PubReader ePub

Purpose
This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients.
Materials and Methods
Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O’Quigley method, and then analyzed in association with prognosis—overall survival (OS), using Cox’s proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis.
Results
Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively).
Conclusion
We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.

Citations

Citations to this article as recorded by

Glucose-to-Lymphocyte Ratio (GLR) as an Independent Prognostic Factor in Patients with Resected Pancreatic Ductal Adenocarcinoma—Cohort Study
Su-Hyeong Park, In-Cheon Kang, Seung-Soo Hong, Ha-Yan Kim, Ho-Kyoung Hwang, Chang-Moo Kang
Cancers.2024; 16(10): 1844. CrossRef
Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study
Ichiro Seto, Hisashi Yamaguchi, Yoshiaki Takagawa, Yusuke Azami, Kanako Takayama, Motohisa Suzuki, Masanori Machida, Yuntao Dai, Nor Shazrina Binti Sulaiman, Yasuhiro Kikuchi, Takahiro Kato, Noriyuki Nishino, Yasushi Teranishi, Masao Murakami
Advances in Radiation Oncology.2024; 9(10): 101577. CrossRef
Predictors of Mortality in Patients with Advanced Cancer—A Systematic Review and Meta-Analysis
Catherine Owusuaa, Simone A. Dijkland, Daan Nieboer, Agnes van der Heide, Carin C. D. van der Rijt
Cancers.2022; 14(2): 328. CrossRef
Prognostic models to predict survival in patients with pancreatic cancer: A systematic review
Liane J. Ioannou, Ashika D. Maharaj, John R. Zalcberg, Jesse T. Loughnan, Daniel G. Croagh, Charles HC. Pilgrim, David Goldstein, James G. Kench, Neil D. Merrett, Arul Earnest, Elizabeth A. Burmeister, Kate White, Rachel E. Neale, Sue M. Evans
HPB.2022;[Epub] CrossRef
Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial
Julie Egea, Julia Salleron, Sophie Gourgou, Ahmet Ayav, Valérie Laurent, Béata Juzyna, Alexandre Harlé, Thierry Conroy, Aurélien Lambert
Cancers.2022; 14(20): 5068. CrossRef
Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade
Jin Shang, Xiao Han, Haoran Zha, Haitao Tao, Xiaoyan Li, Fang Yuan, Guangying Chen, Lijie Wang, Junxun Ma, Yi Hu
Frontiers in Oncology.2021;[Epub] CrossRef
71/m in reduziertem Allgemeinzustand mit Sklerenikterus
M. Schönrock, M. Sinn
Der Onkologe.2021; 27(S1): 109. CrossRef
Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer
Alisa D. Kjaergaard, Inna M. Chen, Astrid Z. Johansen, Børge G. Nordestgaard, Stig E. Bojesen, Julia S. Johansen
Cancers.2021; 13(18): 4599. CrossRef
Peripheral Blood Cell Variables Related to Systemic Inflammation in Patients With Unresectable or Metastatic Pancreatic Cancer
Giuseppe Colloca, Antonella Venturino
Pancreas.2021; 50(8): 1131. CrossRef
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer
Michael Shusterman, Erin Jou, Andreas Kaubisch, Jennifer W. Chuy, Lakshmi Rajdev, Santiago Aparo, Justin Tang, Nitin Ohri, Abdissa Negassa, Sanjay Goel
Journal of Gastrointestinal Cancer.2020; 51(3): 868. CrossRef
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, Peter Brauchli
Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients
Yongping Zhou, Qian Wei, Junsheng Fan, Sijin Cheng, Wenzhou Ding, Zhiyuan Hua
Clinica Chimica Acta.2018; 479: 181. CrossRef
A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma
Irene S. Yu, Winson Y. Cheung
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Declined Preoperative Aspartate Aminotransferase to Neutrophil Ratio Index Predicts Poor Prognosis in Patients with Intrahepatic Cholangiocarcinoma after Hepatectomy
Lingyun Liu, Wei Wang, Yi Zhang, Jianting Long, Zhaohui Zhang, Qiao Li, Bin Chen, Shaoqiang Li, Yunpeng Hua, Shunli Shen, Baogang Peng
Cancer Research and Treatment.2018; 50(2): 538. CrossRef
Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer
Marek Sierzega, Marzena Lenart, Magdalena Rutkowska, Marta Surman, Bozenna Mytar, Andrzej Matyja, Maciej Siedlar, Jan Kulig
Annals of Surgical Oncology.2017; 24(3): 808. CrossRef
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Angélique Vienot, Guillaume Beinse, Christophe Louvet, Louis de Mestier, Aurélia Meurisse, Francine Fein, Bruno Heyd, Denis Cleau, Christelle d’Engremont, Anne-Claire Dupont-Gossart, Zaher Lakkis, Christophe Tournigand, Olivier Bouché, Benoît Rousseau, Ci
JNCI: Journal of the National Cancer Institute.2017;[Epub] CrossRef
Current and future biomarkers for pancreatic adenocarcinoma
Sven H Loosen, Ulf P Neumann, Christian Trautwein, Christoph Roderburg, Tom Luedde
Tumor Biology.2017; 39(6): 101042831769223. CrossRef
Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis
Randy C. Bowen, Nancy Ann B. Little, Joshua R. Harmer, Junjie Ma, Luke G. Mirabelli, Kyle D. Roller, Andrew Mackay Breivik, Emily Signor, Alec B. Miller, Hung T. Khong
Oncotarget.2017; 8(19): 32171. CrossRef

13,984 View
203 Download
16 Web of Science
18 Crossref

Case Report

A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy: Gun Min Kim, Hei-Cheul Jeung, Dokyung Kim, Joo Hoon Kim, Sang Hyun Yoon, Eun Suk Jung, Sang Joon Shin; Cancer Res Treat. 2010;42(4):235-238. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.235

Abstract PDF PubReader ePub

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m² together with cisplatin at 70 mg/m². After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

Citations

Citations to this article as recorded by

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
Liver Cancer.2024; 13(1): 6. CrossRef
A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery
Feng Zhang, Keshu Hu, Bei Tang, Mengxin Tian, Shenxin Lu, Jia Yuan, Miao Li, Rongxin Chen, Zhenggang Ren, Yinghong Shi, Xin Yin
Journal of Gastrointestinal Surgery.2021; 25(4): 971. CrossRef
Treatment of Combined Hepatocellular and Cholangiocarcinoma
Simona Leoni, Vito Sansone, Stefania De Lorenzo, Luca Ielasi, Francesco Tovoli, Matteo Renzulli, Rita Golfieri, Daniele Spinelli, Fabio Piscaglia
Cancers.2020; 12(4): 794. CrossRef
Therapy of Primary Liver Cancer
Mei Feng, Yisheng Pan, Ruirui Kong, Shaokun Shu
The Innovation.2020; 1(2): 100032. CrossRef
Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
Yuka Futsukaichi, Kazuto Tajiri, Saito Kobayashi, Kohei Nagata, Satoshi Yasumura, Terumi Takahara, Masami Minemura, Ichiro Yasuda
Clinical Journal of Gastroenterology.2019; 12(2): 128. CrossRef
Clinical and pathological features of combined hepatocellular–cholangiocarcinoma compared with other liver cancers
Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Masafumi Ohira, Koichi Kato, Yuki Fujii, Ko Sugiyama, Naoki Okada, Takanori Ohata, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Akinobu Taketomi
Journal of Gastroenterology and Hepatology.2019; 34(6): 1074. CrossRef
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score–Matched Study
Yu-Hui Huang, Benjamin V. Park, Yi-Fan Chen, Ron C. Gaba, Grace Guzman, R. Peter Lokken
Journal of Vascular and Interventional Radiology.2019; 30(9): 1317. CrossRef
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigu
Cancer Science.2018; 109(8): 2549. CrossRef
Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma
Lauren S. Chan, Daniel Y. Sze, George A. Poultsides, John D. Louie, Mohammed A. Abdelrazek Mohammed, David S. Wang
CardioVascular and Interventional Radiology.2017; 40(9): 1383. CrossRef
A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy
Jee Eun Choi, Kyung Hee Kim, Seon A Kim, Jung Hwan Lee, Sang Myung Woo, Sang-Jae Park, Eun Kyung Hong, Woo Jin Lee
Korean Journal of Pancreas and Biliary Tract.2016; 21(2): 101. CrossRef
Combined hepatocellular cholangiocarcinoma: Controversies to be addressed
An-Qiang Wang
World Journal of Gastroenterology.2016; 22(18): 4459. CrossRef
Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy
Kathryn Fowler, Nael E. Saad, Elizabeth Brunt, M. B. Majella Doyle, Manik Amin, Neeta Vachharajani, Benjamin Tan, William C. Chapman
Annals of Surgical Oncology.2015; 22(13): 4130. CrossRef
Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity
Kate O’Connor, Joanna C. Walsh, David F. Schaeffer
Annals of Hepatology.2014; 13(3): 317. CrossRef
Transplantation versus resection for patients with combined hepatocellular carcinoma–cholangiocarcinoma
Ryan T. Groeschl, Kiran K. Turaga, T. Clark Gamblin
Journal of Surgical Oncology.2013; 107(6): 608. CrossRef

11,081 View
82 Download
14 Crossref

Original Articles

Wernicke's Encephalopathy in Advanced Gastric Cancer: Eun Suk Jung, Obin Kwon, Soo Hyun Lee, Ki Byung Lee, Joo Hoon Kim, Sang Hyun Yoon, Gun Min Kim, Hei-Cheul Jeung, Sun Young Rha; Cancer Res Treat. 2010;42(2):77-81. Published online June 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.2.77

Abstract PDF PubReader ePub

Purpose

With their prolonged survival and malnutrition, cancer patients, and especially gastrointestinal (GI) tract cancer patients, can develop Wernicke's encephalopathy (WE). The aim of this study is to remind physicians of the importance of WE and prompt management in patients with GI tract cancer.

Materials and Methods

This study is a retrospective review of 2 cases of WE in advanced gastric cancer (AGC) patients, and we review the literature for cases of GI tract cancer related to WE.

Results

A 48-year-old female with AGC presented dizziness and diplopia for 5 days and a 20 kg weight loss. Neurologic exam showed nystagmus and gaze disturbance. Her symptoms improved after daily parenteral injection of thiamine 100 mg for 17 days. A 58-year-old female with AGC presented with sudden disorientation, confusion and 15 kg weight loss. Neurologic exam showed gaze limitation and mild ataxia. Despite daily parenteral injection of thiamine 100 mg for 4 days, she died 5 days after the onset of neurologic symptoms. Combining the cases noted in the literature review with our 2 cases, the 7 gastric cancer cases and 2 colorectal cancer cases related to WE showed similar clinical characteristics; 1) a history of long-period malnutrition and weight loss, 2) relatively typical neurologic signs and symptoms and 3) specific magnetic resonance image findings. Except for 2 patients who had irreversible neurologic symptoms, the other 7 patients were improved with prompt thiamine treatment.

Conclusion

It is important to consider WE in GI tract cancer patients with acute neurologic symptoms and who are in a state of malnutrition. Thiamine should be given as soon as possible when WE is suspected.

Citations

Citations to this article as recorded by

Duodenal Adenocarcinoma in the Setting of Bariatric Surgery: A Perfect Storm for Wernicke’s Encephalopathy
Aliza Gross, Allen T Yu, Jacques Lara-Reyna, Koji Park, Eugenius J Harvey
Cureus.2023;[Epub] CrossRef
Thiamine deficiency in pregnancy and lactation: implications and present perspectives
Ozaifa Kareem, Sobia Nisar, Masood Tanvir, Umar Muzaffer, G. N. Bader
Frontiers in Nutrition.2023;[Epub] CrossRef
Beware of lethal Wernicke's encephalopathy after cytoreductive surgery with HIPEC for peritoneal pseudomyxoma: Case report of morbidity and mortality review
Oumayma Lahnaoui, Nezha EL Bahaoui, Sara El Atiq, Laila Amrani, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine, Amine Souadka
International Journal of Surgery Case Reports.2022; 98: 107500. CrossRef
Thiamine deficiency unrelated to alcohol consumption in high‐income countries: a literature review
Filomena Gomes, Gilles Bergeron, Megan W. Bourassa, Philip R. Fischer
Annals of the New York Academy of Sciences.2021; 1498(1): 46. CrossRef
WERNICKE ENCEPHALOPATHY IN A PATIENT WITH GASTRIC CANCER RECURRENCE AFTER UPPER GASTROINTESTINAL SURGERY: A CASE REPORT AND REVIEW OF THE LITERATURE
Zining Liu, Xin Ye, Jiejin Yang, Zeyang Chen
Gastroenterology Nursing.2020; 43(6): 463. CrossRef
Wernicke's encephalopathy in a subject with enter-colic fistula
Daniele Canova, Paola Scalon, Fabio Monica, Stefano A. Grassi, Anna Giacomin, Tiziana Tumelero, Gaetano Mastropaolo, Francesco Malfa
Gazzetta Medica Italiana Archivio per le Scienze Mediche.2019;[Epub] CrossRef
Wernicke's encephalopathy in a patient with non-Hodgkin's lymphoma post-Autologous HSCT
João Paulo de Vasconcelos Leitão, Romélia Pinheiro Gonçalves Lemes, Maritza Cavalcante Barbosa, Beatriz Stela Gomes de Souza Pitombeira Araújo, Karine Sampaio Nunes Barroso, Jacques Kaufman, Talyta Ellen de Jesus dos Santos, Anna Thawanny Gadelha Moura, A
Revista da Associação Médica Brasileira.2018; 64(10): 882. CrossRef
Wernicke encephalopathy as initial presentation of lymphoma
Ju Hyun Seo, Ju Hee Kim, Der Sheng Sun, Hye Sung Won, Jeong Wook Park, Yoon Ho Ko
The Korean Journal of Internal Medicine.2017; 32(6): 1112. CrossRef
The Role of Thiamine and Effects of Deficiency in Dogs and Cats
Georgia Kritikos, Jacqueline Parr, Adronie Verbrugghe
Veterinary Sciences.2017; 4(4): 59. CrossRef
Association between malignancy and non-alcoholic Wernicke's encephalopathy: a case report and literature review
Evan Y. Choi, William A. Gomes, Missak Haigentz, Jerome J. Graber
Neuro-Oncology Practice.2016; 3(3): 196. CrossRef
Wernicke encephalopathy as rare complication of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Antonio Macrì, Francesco Fleres, Antonio Ieni, Maurizio Rossitto, Tommaso Mandolfino, Salvatore Micalizzi, Francesco Iaropoli, Carmelo Mazzeo, Massimo Trovato, Eugenio Cucinotta, Edoardo Saladino
International Journal of Surgery Case Reports.2015; 16: 29. CrossRef
Two Cases of Wernicke's Encephalopathy That Developed during Total Parenteral Nutrition in Colon Cancer Patients Treated with 5-Fluorouracil-based Chemotherapy
Kyung Pyo Cho, Jae Sung Lee, Ji Seok Seong, Yong Moon Woo, Young Jun Cho, Beom Jin Jeong, Jee Hoon Sohn, Su-Jung Kim
The Korean Journal of Gastroenterology.2014; 64(3): 158. CrossRef
Wernicke's encephalopathy in a patient with gastric carcinoma: a diagnosis not to miss
Chandrashekar Udyavara Kudru, Shivashankara Kaniyoor Nagiri, Sandeep Rao
BMJ Case Reports.2014; : bcr2013203511. CrossRef
Wernicke-Korsakoff Syndrome in Primary Peritoneal Cancer
Ki Hyang Kim
Case Reports in Oncology.2013; 6(3): 593. CrossRef

12,075 View
86 Download
14 Crossref

Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials: Hong Jae Chon, Sun Young Rha, Chong Kun Im, Chan Kim, Min Hee Hong, Hye Ryun Kim, Jung Ryun An, Sung Hoon Noh, Hyun Cheol Chung, Hei-Cheul Jeung; Cancer Res Treat. 2009;41(4):196-204. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.196

Abstract PDF PubReader ePub

Purpose

This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer.

Materials and Methods

Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m²) or docetaxel (DFL; 75 mg/m²) on day 1, followed by a bolus of LV (20 mg/m² days 1~3) and a 24-hour infusion of 5-FU (1,000 mg/m² days 1~3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity.

Results

Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2~6.5 months) for DFL and 3.3 months (95% CI, 1.3~5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2~12.5 months] and 13.9 months [95% CI, 10.9~19.2 months], respectively; p=0.37). The most frequent grade 3~4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL.

Conclusion

Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by

Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Diala Merheb, Georgette Dib, Maroun Bou Zerdan, Clara El Nakib, Saada Alame, Hazem I. Assi
Current Cancer Drug Targets.2022; 22(1): 49. CrossRef
Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef
Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy
Tore B. Stage, Shuiying Hu, Alex Sparreboom, Deanna L. Kroetz
Clinical and Translational Science.2021; 14(2): 460. CrossRef
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.
Cancer Discovery.2021; 11(2): 308. CrossRef
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy
Giulia Fumagalli, Laura Monza, Guido Cavaletti, Roberta Rigolio, Cristina Meregalli
Frontiers in Immunology.2021;[Epub] CrossRef
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems
Nathan P. Staff, Jill C. Fehrenbacher, Martial Caillaud, M. Imad Damaj, Rosalind A. Segal, Sandra Rieger
Experimental Neurology.2020; 324: 113121. CrossRef
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
Wan-Cai Que, Yan-Fang Huang, Xiao-Yan Lin, Yan-Qin Lan, Xin-Yan Gao, Xin-Li Wang, Ri-Ping Wu, Bin Du, Xiao-Bin Huang, Hong-qiang Qiu, Dong-Ta Zhong
Anti-Cancer Drugs.2019; 30(3): 302. CrossRef
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer
Chan Kim, Hong Jae Chon, Joo Hoon Kim, Minkyu Jung, Chung Mo Nam, Hyo Song Kim, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
European Journal of Cancer.2019; 112: 20. CrossRef
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-K
The Lancet Oncology.2017; 18(5): 640. CrossRef
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova, Irina Vetter
Frontiers in Molecular Neuroscience.2017;[Epub] CrossRef
Identifying therapeutic targets in gastric cancer: the current status and future direction
Beiqin Yu, Jingwu Xie
Acta Biochimica et Biophysica Sinica.2016; 48(1): 90. CrossRef
Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy
Kyoji Taguchi
YAKUGAKU ZASSHI.2016; 136(2): 287. CrossRef
Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer
Chunmei Shi, Qiang Chen, Songfei Shen, Riping Wu, Baoyu Yang, Qing Liu, Qian Xu
Expert Review of Anticancer Therapy.2015; 15(5): 595. CrossRef
Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin
HYUN SU LEE, JUN BEOM PARK, MYUNG SUN LEE, EUN YOUNG CHA, JI YEON KIM, JI YOUNG SUL
Molecular Medicine Reports.2015; 12(3): 4782. CrossRef
Paclitaxel-based regimens as first-line treatment in advanced gastric cancer
Zengqing Guo, Xiaojie Wang, Rongbo Lin, Ling Chen, Nanfeng Fan, Yu Chen, Jinyuan Lin, Jiami Yu
Journal of Chemotherapy.2015; 27(2): 94. CrossRef
A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer
Rongbo Lin, Nanfeng Fan, Guangfeng Wu, Ying Chen, Zengqing Guo, Xiaojie Wang, Feng Jin, Ling Chen, Jie Liu
Journal of Chemotherapy.2015; 27(1): 52. CrossRef
Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer
MEIQIN YUAN, YUNSHAN YANG, WANGXIA LV, ZHENGBO SONG, HAIJUN ZHONG
Oncology Letters.2014; 8(1): 351. CrossRef
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou, Jordi Bruna, Paola Marmiroli, Guido Cavaletti
Critical Reviews in Oncology/Hematology.2012; 82(1): 51. CrossRef
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
W. Grisold, G. Cavaletti, A. J. Windebank
Neuro-Oncology.2012; 14(suppl 4): iv45. CrossRef
Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)
Florian Weissinger, Marc Reymond, Klaus Dumke, Martin Krüger
Onkologie.2011; 34(10): 548. CrossRef
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
Kyung-Hun Lee, Hyung-Seok Hur, Seock-Ah Im, Juhee Lee, Hwang-Phill Kim, Young-Kwang Yoon, Sae-Won Han, Sang-Hyun Song, Do-Youn Oh, Tae-You Kim, Yung-Jue Bang
Cancer Letters.2010; 299(1): 22. CrossRef

12,097 View
76 Download
22 Crossref

Prognosis of pN3 Stage Gastric Cancer: Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha; Cancer Res Treat. 2009;41(2):73-79. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.73

Abstract PDF PubReader ePub

Purpose

The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.

Materials and Methods

Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.

Results

Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p<0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.

Conclusion

The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.

Citations

Citations to this article as recorded by

GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis
Dilara Ataseven, Şeyma Taştemur, Fatih Yulak, Sebahattin Karabulut, Mustafa Ergul
Toxicology in Vitro.2023; 90: 105610. CrossRef
HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3
Wei-Jie Zang, Yi-Lin Hu, Chen-Yu Qian, Ying Feng, Jia-Zhou Liu, Jun-Ling Yang, Hua Huang, Yi-Zhun Zhu, Wan-Jiang Xue
British Journal of Cancer.2022; 127(2): 237. CrossRef
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer
Zhe Gong, Jieyun Zhang, Weijian Guo
Cancer Medicine.2020; 9(23): 9052. CrossRef
S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer
Yan Li, Xiao-Yu Li, Li-Xiang Li, Ru-Chen Zhou, Yinhe Sikong, Xiang Gu, Bi-Ying Jin, Bing Li, Yan-Qing Li, Xiu-Li Zuo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Oncología personalizada: principales biomarcadores en el pronóstico y tratamiento de tumores sólidos
Marta Molina Romero, Emilio José Laserna Mendieta, Gema María Varo Sánchez, María Concepción Alonso-Cerezo, María Orera Clemente
Revista del Laboratorio Clínico.2019; 12(3): e1. CrossRef
Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?
J. Zhang, S. Zou, R. Luo, Z. Zhu, Z. Wang, H. Xu, B. Huang
Clinical and Translational Oncology.2019; 21(12): 1699. CrossRef
Reduced expression of Rap1GAP as a prognostic biomarker for primary gastric cancer patients
Jingjing Zhao, Cong Mai, Desheng Weng, Changlong Chen, Ziqi Zhou, Yuan Liu, Zhiwei Zhou, Peng Wang
Cancer Biomarkers.2018; 22(3): 375. CrossRef
Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection
Sung Jin Oh, Byoung Jo Suh, Jong Kwon Park, Sung Don Oh, Hang Jong Yu
Case Reports in Oncology.2017; 10(1): 57. CrossRef
Gastric biomarkers: a global review
Nick Baniak, Jenna-Lynn Senger, Shahid Ahmed, S. C. Kanthan, Rani Kanthan
World Journal of Surgical Oncology.2016;[Epub] CrossRef
MiR 21‐5p as a predictor of recurrence in young gastric cancer patients
Soo‐Kyung Park, Young Soo Park, Ji Yong Ahn, Eun‐Ju Do, Dongho Kim, Jee Eun Kim, kyoungwon Jung, Jeong‐Sik Byeon, Byong Duk Ye, Dong Hoon Yang, Sang Hyoung Park, Sung Wook Hwang, Hwoon‐Yong Jung, Seung‐Jae Myung
Journal of Gastroenterology and Hepatology.2016; 31(8): 1429. CrossRef
Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer
Dongying Gu, Mulong Du, Cuiju Tang, Haiyan Chu, Zhi Xu, Xinyin Huo, Weida Gong, Yongfei Tang, Jianwei Zhou, Na Tong, Yong Xu, Zhengdong Zhang, Meilin Wang, Jinfei Chen
Environmental and Molecular Mutagenesis.2014; 55(5): 421. CrossRef
Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer
Bang Wool Eom, Jungnam Joo, Young-Woo Kim, Daniel Reim, Ji Yeon Park, Hong Man Yoon, Keun Won Ryu, Jong Yeul Lee, Myeong-Cherl Kook
Surgery.2014; 155(3): 408. CrossRef
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer
Yonghui Wu, Heike Grabsch, Tatiana Ivanova, Iain Beehuat Tan, Jacinta Murray, Chia Huey Ooi, Alexander Ian Wright, Nicholas P West, Gordon G A Hutchins, Jeanie Wu, Minghui Lee, Julian Lee, Jun Hao Koo, Khay Guan Yeoh, Nicole van Grieken, Bauke Ylstra, Sun
Gut.2013; 62(8): 1100. CrossRef
Validity and Necessity of Sub-classification of N3 in the 7thUICC TNM Stage of Gastric Cancer
Fang-Xuan Li, Ru-Peng Zhang, Han Liang, Ji-Chuan Quan, Hui Liu, Hui Zhang
Asian Pacific Journal of Cancer Prevention.2013; 14(3): 2091. CrossRef
Is the New Seventh AJCC/UICC Staging System Appropriate for Patients with Gastric Cancer?
Hong Man Yoon, Keun Won Ryu, Byung Ho Nam, Soo Jeong Cho, Sook Ryun Park, Jong Yeul Lee, Jun Ho Lee, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim
Journal of the American College of Surgeons.2012; 214(1): 88. CrossRef
Comparison of the 6th and 7th Editions of the UICC TNM Staging System for Gastric Cancer: Results of a Chinese Single-Institution Study of 1,503 Patients
Wei Wang, Xiao-wei Sun, Chao-feng Li, Lin Lv, Yuan-fang Li, Ying-bo Chen, Da-zhi Xu, Rajiv Kesari, Chun-yu Huang, Wei Li, You-qing Zhan, Zhi-wei Zhou
Annals of Surgical Oncology.2011; 18(4): 1060. CrossRef

11,892 View
76 Download
16 Crossref

Case Report

A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and Taxane-based Neoadjuvant Chemotherapy: A Case Report: Se Hyun Kim, Hyun Cheol Chung, Jaeheon Jeong, Ji Hoon Kim, Sun Young Rha, Joong Bae Ahn, Nam Hoon Cho, Hei-Cheul Jeung; Cancer Res Treat. 2007;39(3):134-137. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.134

Abstract PDF PubReader ePub

Atypical medullary carcinomas and carcinosarcoma have unique histopathological features. Here we present a case with a breast malignancy that had pathological characteristics of both. A 54-year old patient with a malignant breast mass received 6 cycles of adriamycin-based chemotherapy, followed by 3 cycles of paclitaxel monotherapy, and had a poor clinical response to treatment. A modified radical mastectomy was performed. The pathological diagnosis was complicated by an inability to distinguish between atypical medullary carcinoma and carcinosarcoma. The findings included a tumor that was well-circumscribed, high grade and a syncytial growth pattern as well as biphasic sarcomatous and carcinomatous characteristics. In conclusion, atypical medullary carcinoma and carcinosarcoma of the breast have entirely different prognoses and should be managed differently. Both should be treated by surgical resection, and additional therapy should be considered based on the cancer with the poorer prognosis.

Citations

Citations to this article as recorded by

Carcinosarcoma of the breast: Facing the challenge of a rare nosologic entity
Aikaterini Mastoraki, Maria Tsamopoulou, Foivos-Konstantinos Stamatis, Alexios Strimpakos, Ero Mouchtouri, Christiana Panagi, Evgenia Mela, Sotiria Mastoraki, Aristotelis Kechagias, Dimitrios Schizas
World Journal of Clinical Cases.2025;[Epub] CrossRef
A Rare Case of Primary Carcinosarcoma of the Breast
Maria Kiakou, Maria Tolia, Nektarios Koufopoulos, Konstantinos Tsapakidis, Eleni Arvanitou, Gkikas Konstantinos, Nikolaos Charalambakis, Michalis Nikolaou, Dimitrios Matthaios, Nikolaos Tsoukalas
Forum of Clinical Oncology.2022; 13(1): 48. CrossRef
Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature
Gunjesh Kumar Singh, Pragya Singh, KT Bhowmik
Indian Journal of Medical and Paediatric Oncology.2018; 39(03): 400. CrossRef
Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman
Matteo Ghilli, Donatella M. Mariniello, Giovanni Fanelli, Francesca Cascione, Andrea Fontana, Agostino Cristaudo, Anna Cilotti, Adelaide M. Caligo, Giampiero Manca, Livio Colizzi, Antonio G. Naccarato, Manuela Roncella
Clinical Breast Cancer.2017; 17(1): e31. CrossRef

9,513 View
70 Download
4 Crossref

Original Article

An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions: Ki-Yeol Kim, Se Hyun Kim, Dong Hyuk Ki, Jaeheon Jeong, Ha Jin Jeong, Hei-Cheul Jeung, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2007;39(2):74-81. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.74

Abstract PDF PubReader ePub

Purpose

The diverse experimental environments in microarray technology, such as the different platforms or different RNA sources, can cause biases in the analysis of multiple microarrays. These systematic effects present a substantial obstacle for the analysis of microarray data, and the resulting information may be inconsistent and unreliable. Therefore, we introduced a simple integration method for combining microaray data sets that are derived from different experimental conditions, and we expected that more reliable information can be detected from the combined data set rather than from the separated data sets.

Materials and Methods

This method is based on the distributions of the gene expression ratios among the different microarray data sets and it transforms, gene by gene, the gene expression ratios into the form of the reference data set. The efficiency of the proposed integration method was evaluated using two microarray data sets, which were derived from different RNA sources, and a newly defined measure, the mixture score.

Results

The proposed integration method intermixed the two data sets that were obtained from different RNA sources, which in turn reduced the experimental bias between the two data sets, and the mixture score increased by 24.2%. A data set combined by the proposed method preserved the inter-group relationship of the separated data sets.

Conclusion

The proposed method worked well in adjusting systematic biases, including the source effect. The ability to use an effectively integrated microarray data set yields more reliable results due to the larger sample size and this also decreases the chance of false negatives.

Citations

Citations to this article as recorded by

spatiAlign: an unsupervised contrastive learning model for data integration of spatially resolved transcriptomics
Chao Zhang, Lin Liu, Ying Zhang, Mei Li, Shuangsang Fang, Qiang Kang, Ao Chen, Xun Xu, Yong Zhang, Yuxiang Li
GigaScience.2024;[Epub] CrossRef
AMDBNorm: an approach based on distribution adjustment to eliminate batch effects of gene expression data
Xu Zhang, Zhiqiang Ye, Jing Chen, Feng Qiao
Briefings in Bioinformatics.2022;[Epub] CrossRef
reComBat: batch-effect removal in large-scale multi-source gene-expression data integration
Michael F Adamer, Sarah C Brüningk, Alejandro Tejada-Arranz, Fabienne Estermann, Marek Basler, Karsten Borgwardt, Thomas Lengauer
Bioinformatics Advances.2022;[Epub] CrossRef
Harmonization strategies for multicenter radiomics investigations
R Da-Ano, D Visvikis, M Hatt
Physics in Medicine & Biology.2020; 65(24): 24TR02. CrossRef
A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies
Gift Nyamundanda, Pawan Poudel, Yatish Patil, Anguraj Sadanandam
Scientific Reports.2017;[Epub] CrossRef
Batch effect removal methods for microarray gene expression data integration: a survey
C. Lazar, S. Meganck, J. Taminau, D. Steenhoff, A. Coletta, C. Molter, D. Y. Weiss-Solis, R. Duque, H. Bersini, A. Nowe
Briefings in Bioinformatics.2013; 14(4): 469. CrossRef
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Jae-Jun Jung, Tae Soo Kim, Ho Jeong Kwon, Byung Soo Kim, Hyun Cheol Chung
Journal of Cancer Research and Clinical Oncology.2010; 136(12): 1901. CrossRef

9,670 View
69 Download
7 Crossref

Case Report

Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports: Jong Keun Lim, Joong Bae Ahn, Sung Ha Cheon, Hyun Chang, Jong Yul Jung, Sun Young Rha, Jae Kyung Roh, Sung Hoon Noh, Ho Geun Kim, Hyun Cheol Chung, Hei-Cheul Jeung; Cancer Res Treat. 2006;38(3):184-188. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.184

Abstract PDF PubReader ePub

Surgical resection of colorectal cancer metastasis to the liver results in a 5-year survival rate of around 40%. Liver metastasis from other cancers such as neuroendocrine carcinoma and genitourinary tumors are also treated effectively with combined liver resection. However, hepatic metastasectomy for liver tumor from gastric cancer hasn't been considered as a standard treatment, and the benefit for this treatment has not been established. We report here on two cases of gastrectomy and combined liver resection for synchronous liver metastasis without any evidence of other metastatic lesions, and these two patients have survived for more than 7 years without evidence of disease recurrence. In conclusion, for patients with hepatic metastasis from gastric cancer, combined surgical resection of the liver metastasis should be considered as a treatment option when metastasis to other sites can be excluded.

Citations

Citations to this article as recorded by

Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer
Guo-Liang Yao
World Journal of Gastroenterology.2015; 21(9): 2754. CrossRef

8,960 View
73 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search